Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ASP1707 in Healthy Subjects
NCT02368912Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opigolix in endometriosis and prostate cancer (PCa) (9 arms), sponsored by Astellas Pharma. Primary endpoints: Safety assessed by nature, frequency and severity of adverse events, Safety assessed by physical examination and 19 more. Started Jun 2010; status: completed.
02
Drugs
opigolix
03
Conditions
endometriosisprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02368912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368912.